Phase II study of L-asparaginase in the treatment of pancreatic carcinoma

H. E. Lessner; S. Valenstein; R. Kaplan; P. DeSimone; A. Yunis

Phase II study of L-asparaginase in the treatment of pancreatic carcinoma

H. E. Lessner, S. Valenstein, R. Kaplan, P. DeSimone, A. Yunis

Medicine

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

L-Asparaginase was given to ten patients with advanced nonresectable pancreatic carcinoma because of the demonstration of in vitro sensitivity of the tumor to the drug. No therapeutic value was demonstrated for L-asparaginase. Toxicity was significant, mainly as evidenced by increasing mental confusion and early signs of a coagulopathy. On the basis of this limited study, L-asparaginase seems to have no value in advanced pancreatic carcinoma. The usefulness of L-asparaginase as primary therapy in patients with less advanced disease remains to be determined.

Original language	English (US)
Pages (from-to)	1359-1361
Number of pages	3
Journal	Cancer treatment reports
Volume	64
Issue number	12
State	Published - 1980

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

Fingerprint Dive into the research topics of 'Phase II study of L-asparaginase in the treatment of pancreatic carcinoma'. Together they form a unique fingerprint.

Cite this

@article{cf1261bc8f504acc96ab1f6fe3a892ef,

title = "Phase II study of L-asparaginase in the treatment of pancreatic carcinoma",

abstract = "L-Asparaginase was given to ten patients with advanced nonresectable pancreatic carcinoma because of the demonstration of in vitro sensitivity of the tumor to the drug. No therapeutic value was demonstrated for L-asparaginase. Toxicity was significant, mainly as evidenced by increasing mental confusion and early signs of a coagulopathy. On the basis of this limited study, L-asparaginase seems to have no value in advanced pancreatic carcinoma. The usefulness of L-asparaginase as primary therapy in patients with less advanced disease remains to be determined.",

author = "Lessner, {H. E.} and S. Valenstein and R. Kaplan and P. DeSimone and A. Yunis",

year = "1980",

language = "English (US)",

volume = "64",

pages = "1359--1361",

journal = "Journal of the National Cancer Institute",

issn = "0027-8874",

publisher = "Oxford University Press",

number = "12",

}

TY - JOUR

T1 - Phase II study of L-asparaginase in the treatment of pancreatic carcinoma

AU - Lessner, H. E.

AU - Valenstein, S.

AU - Kaplan, R.

AU - DeSimone, P.

AU - Yunis, A.

PY - 1980

Y1 - 1980

N2 - L-Asparaginase was given to ten patients with advanced nonresectable pancreatic carcinoma because of the demonstration of in vitro sensitivity of the tumor to the drug. No therapeutic value was demonstrated for L-asparaginase. Toxicity was significant, mainly as evidenced by increasing mental confusion and early signs of a coagulopathy. On the basis of this limited study, L-asparaginase seems to have no value in advanced pancreatic carcinoma. The usefulness of L-asparaginase as primary therapy in patients with less advanced disease remains to be determined.

AB - L-Asparaginase was given to ten patients with advanced nonresectable pancreatic carcinoma because of the demonstration of in vitro sensitivity of the tumor to the drug. No therapeutic value was demonstrated for L-asparaginase. Toxicity was significant, mainly as evidenced by increasing mental confusion and early signs of a coagulopathy. On the basis of this limited study, L-asparaginase seems to have no value in advanced pancreatic carcinoma. The usefulness of L-asparaginase as primary therapy in patients with less advanced disease remains to be determined.

UR - http://www.scopus.com/inward/record.url?scp=0019293446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019293446&partnerID=8YFLogxK

M3 - Article

C2 - 7471124

AN - SCOPUS:0019293446

VL - 64

SP - 1359

EP - 1361

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 12

ER -